Skip to main content

Advertisement

SpringerLink
Log in

The Clinical Evaluation of Tegafur Gimeracil Oteracil Combined with THP and DDP for Second-Line Treatment of Advanced Cardiac Carcinoma

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

The aim of this study is to explore the clinical effect of tegafur gimeracil oteracil combined with pirarubicin hydrochloride (THP) and diamminedichloroplatinum (DDP) for second-line treatment of advanced cardiac carcinoma, and find the most effective method to improve its survival rate and decrease the adverse reactions. 70 patients with advanced cardiac carcinoma admitted during February 2010–March 2014 were selected and divided into two groups with 35 cases in each group. All patients were treated with THP and DDP, and tegafur gimeracil oteracil was added to the observation group. The differences of effective rate, life quality, and adverse reactions after treatment in observational group were observed. The result of total curative effect indicated that the occurrence rate of complete remission + partial remission (CR + PR) in the control group was 28.57 %, the total effective rate was 51.43 %, the occurrence rate of CR + PR in the observational group was 34.29 %, and the total effective rate was 57.15 %; there was no statistical difference between the two groups (P > 0.05). The result of KPS scoring indicated that the improvement rate in the control group was 28.57 %, the total effective rate was 62.86 %, the improvement rate in the observational group was 42.86 %, and the total effective rate was 80 %; there was statistical difference between two groups (P < 0.05); the occurrence rates of adverse reactions including leukocyte decrease, thrombocytopenia, anemia, nausea and vomiting, constipation, peripheral neurovirulence, hepatotoxicity, and renal toxicity were statistically different (P < 0.05). Tegafur gimeracil oteracil combined with THP and DDP in treating advanced cardiac carcinoma can improve the life quality and decrease the adverse reactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bjelovic, M., et al. (2003). History of surgery of stomach and cardial carcinoma. Acta Chirurgica Iugoslavica, 50(2), 11–17.

    CAS  PubMed  Google Scholar 

  2. Schmitz, H. C., et al. (2004). The use of ultrasound and computed tomography for the diagnosis of a squamous cell carcinoma of the oesophago-cardial region of the stomach in a rhesus monkey. Laboratory Animals, 38(1), 92–97.

    Article  CAS  PubMed  Google Scholar 

  3. Surendiran, A., et al. (2010). Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study. Indian Journal of Pharmacology, 42(1), 40–43.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Doi, C., et al. (2007). Monitoring sheet covering long-term chemotherapy to predict individual adverse reaction patterns for patients with gynecologic chemotherapy. Yakugaku Zasshi, 127(6), 1027–1033.

    Article  CAS  PubMed  Google Scholar 

  5. Cao, Y., Li, P., & Tan, K. J. (2006). Clinical observation on shenmai injection in preventing and treating adverse reaction of chemotherapy on advanced non-small cell lung cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi, 26(6), 550–552.

    PubMed  Google Scholar 

  6. Duh, D., & Warnez, M. (2013). Tegafur/gimeracil/oteracil (Teysuno), by oral administration. Journal de Pharmacie de Belgique, 4, 35–36.

    PubMed  Google Scholar 

  7. Li, F., et al. (2014). Tegafur gimeracil oteracil potassium capsule induced acute interstitial lung disease: A case report. Zhongguo Fei Ai Za Zhi, 17(1), 53–56.

    CAS  PubMed  Google Scholar 

  8. Ishizuna, K., et al. (2014). Effectiveness and safety of tegafur-gimeracil-oteracil potassium(TS-1) for metastatic breast cancer: A single-center retrospective study. Gan To Kagaku Ryoho, 41(13), 2577–2582.

  9. Kawahara, H., et al. (2012). Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil and oteracil potassium) for colorectal cancer. Hepato-Gastroenterology, 59(113), 134–137.

    CAS  PubMed  Google Scholar 

  10. Heradstveit, B. E., et al. (2012). Factors complicating interpretation of capnography during advanced life support in cardiac arrest—a clinical retrospective study in 575 patients. Resuscitation, 83(7), 813–818.

    Article  PubMed  Google Scholar 

  11. Gao, S. G., et al. (2011). Therapeutic effects of combined oxaliplatin and S-1 in older patients with advanced gastric cardiac adenocarcinoma. World Journal of Gastroenterology, 17(47), 5221–5226.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Hattori, S., et al. (2012). Metastatic urothelial carcinoma to pericardia manifested by dyspnea from cardiac tamponade during systemic chemotherapy: Case report and literature review. Canadian Urological Association Journal, 6(5), E184–E188.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Panella, M., et al. (2010). Cardiac sudden death as a result of acute coronary artery thrombosis during chemotherapy for testicular carcinoma. Journal of Forensic Sciences, 55(5), 1384–1388.

    Article  Google Scholar 

  14. Bazine, A., et al. (2014). Cardiac metastases of renal cell carcinoma revealed by syncope: Diagnosis and treatment. Case Rep Oncol, 7(2), 560–564.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Dasgupta, T., Barani, I. J., & Roach, M., 3rd. (2011). Successful radiation treatment of anaplastic thyroid carcinoma metastatic to the right cardiac atrium and ventricle in a pacemaker-dependent patient. Radiation Oncology, 6, 16.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Gao, J., et al. (2010). Successful treatment of acute hemorrhagic cardiac temponade in a patient with hepatocellular carcinoma during percutaneous radiofrequency ablation. Chinese Medical Journal (Engl), 123(11), 1470–1472.

    Google Scholar 

  17. Bustamante, J., et al. (2010). Cardiac surgery in the treatment of renal cell carcinoma with vena cava involvement. Cirugía Española, 87(3), 182–184.

    Article  PubMed  Google Scholar 

  18. Crile, G., Jr, Effler, D. B., & Scheid, J. E. (1950). Carcinoma of the cardiac portion of stomach; treatment by use of the thoraco-abdominal approach. Cleveland Clinic Quarterly, 17(3), 154–159.

    Article  PubMed  Google Scholar 

  19. Otsuka, H. et al. (2013). Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer. Breast Cancer.

  20. Yamamoto, Y., et al. (2012). A case of advanced cutaneous squamous cell carcinoma of the lower eyelid that was successfully treated with tegafur-gimeracil-oteracil potassium monotherapy. Journal of the American Academy of Dermatology, 67(5), e233–e234.

    Article  PubMed  Google Scholar 

  21. Kobayakawa, M., & Kojima, Y. (2011). Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: A review comparing it with other fluoropyrimidine-based therapies. Onco Targets and Therapy, 4, 193–201.

    Article  CAS  Google Scholar 

  22. Inoue, S., et al. (2007). Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium. Drug Metabolism and Pharmacokinetics, 22(3), 162–168.

    Article  CAS  PubMed  Google Scholar 

  23. Petibon, Y., et al. (2013). Cardiac motion compensation and resolution modeling in simultaneous PET-MR: A cardiac lesion detection study. Physics in Medicine & Biology, 58(7), 2085–2102.

    Article  CAS  Google Scholar 

  24. Sakai, A., et al. (2008). Marked effect of combination chemotherapy with tegafur-gimeracil-oteracil potassium and gemcitabine on a suspected case of pancreas cancer or gallbladder cancer metastasis to bone: Further diagnosis of disseminated carcinomatosa of bone marrow recurrence after the 23 years of gastric cancer operation by autopsy findings. Gan To Kagaku Ryoho, 35(3), 529–532.

    PubMed  Google Scholar 

  25. Liau, B., et al. (2011). Pluripotent stem cell-derived cardiac tissue patch with advanced structure and function. Biomaterials, 32(35), 9180–9187.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Tsuda, A., et al. (2008). The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium. Cancer Chemotherapy and Pharmacology, 62(3), 427–432.

    Article  CAS  PubMed  Google Scholar 

  27. Rosini, J. M., & Hollinger, M. K. (2012). Advanced cardiac life support: What’s new, what’s old? Journal of Emergency Nursing, 38(4), 398–400.

    Article  PubMed  Google Scholar 

  28. Davies, A. R. (1979). Advanced cardiac life support: An imperative for physicians. The Ohio State Medical Journal, 75(6), 356–358.

    CAS  PubMed  Google Scholar 

  29. Matt, P., et al. (2011). The European Medicines Agency review of tegafur/gimeracil/oteracil (Teysuno) for the treatment of advanced gastric cancer when given in combination with cisplatin: Summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP). Oncologist, 16(10), 1451–1457.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

The authors have not declared any conflicts of interest.

Author information

Authors and Affiliations

  1. Gastrointestinal Tumor Surgery Department, Shaoxing People’s Hospital, Zhejiang University, Shaoxing, 312000, Zhejiang, People’s Republic of China

    Hai-feng Wang & Jie-qing Lv

Authors
  1. Hai-feng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jie-qing Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hai-feng Wang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Hf., Lv, Jq. The Clinical Evaluation of Tegafur Gimeracil Oteracil Combined with THP and DDP for Second-Line Treatment of Advanced Cardiac Carcinoma. Cell Biochem Biophys 72, 695–699 (2015). https://doi.org/10.1007/s12013-015-0520-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-015-0520-0

Keywords

Search

Navigation